ALSP Orchid Acquisition Corporation I (ALORU) Stock Analysis
DELISTED 2023
What happened to ALSP Orchid Acquisition Corporation I (ALORU) stock?
ALSP Orchid Acquisition Corporation I (ALORU) no longer trades on public markets. It was delisted in November 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ALSP Orchid Acquisition Corporation I (ALORU) trades at $10.84. ALSP Orchid Acquisition Corporation I is a special purpose acquisition company (SPAC) focused on merging with a life science business. Market cap: $78.0M, Sector: Financial services.
Last analyzed: Mar 17, 2026Analyst Coverage for ALORU: ALORU does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALORU against Financial Services peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
ALSP Orchid Acquisition Corporation I (ALORU) Financial Services Profile
ALSP Orchid Acquisition Corporation I is a blank check company targeting a merger with a life science business in North America or Singapore. As a SPAC, its value is tied to its ability to identify and acquire a promising target, making it a speculative investment within the financial services sector.
What Is the Investment Thesis for ALORU?
ALSP Orchid Acquisition Corporation I presents a speculative investment opportunity tied to its ability to identify and acquire a promising life science company. With a market capitalization of $78.0M and a high P/E ratio of 692.31, the company's valuation is largely based on the potential of a future merger. Key value drivers include the management team's expertise in the life sciences sector and their network for sourcing potential targets. The primary risk lies in the possibility of failing to find a suitable target within the given timeframe, which could lead to the liquidation of the SPAC and a loss of investment. Success hinges on the quality and growth potential of the acquired company.
Based on FMP financials and quantitative analysis
ALORU Key Highlights
Market capitalization of $78.0M, reflecting investor expectations for a successful acquisition.
- P/E ratio of 692.31, indicating a valuation based on future earnings potential following a merger.
- Focus on life science companies in North America and Singapore, targeting a high-growth sector.
- No dividend yield, as the company is focused on deploying capital for acquisitions.
- Incorporated in 2021, providing a limited timeframe to complete a business combination.
Who Are ALORU's Competitors?
ALORU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARTE Artemis Strategic Investment Corporation | $10.74 | +0.19% | $76.7M | 44 |
| CBRG Chain Bridge I | $4.06 | -5.36% | $18.0M | 44 |
| CHAA Catcha Investment Corp | $8.90 | +7.23% | $77.6M | 44 |
| CXAI CXApp Inc. | $3.94 | -14.16% | $8.60M | — |
| MDAI Spectral AI, Inc. | $1.57 | -3.09% | $50.0M | — |
| RCLFU Rosecliff Acquisition Corp I | $11.33 | +11.74% | $77.2M | 62 |
| MMTXU Miluna Acquisition Corp is a blank check company incorporated in 2025, focusing on mergers, acquisitions, and similar business combinations. The company | $10.75 | +6.44% | $82.7M | 65 |
| CPBI Central Plains Bancshares, Inc. | $20.97 | +0.24% | $87.7M | 78 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALORU's Key Strengths?
Experienced management team with life sciences expertise.
- Access to capital through IPO.
- Focus on high-growth life sciences sector.
- Flexibility to target companies in North America and Singapore.
What Are ALORU's Weaknesses?
Dependence on identifying and acquiring a suitable target.
- Limited operating history.
- Potential for shareholder dilution through warrant exercises.
- Competition from other SPACs.
What Could Drive ALORU Stock Higher?
Announcement of a definitive merger agreement with a target company.
- Completion of the merger and commencement of trading under a new ticker symbol.
- Positive clinical trial results or regulatory approvals for the acquired company's products.
- Expansion of the acquired company's market share and revenue growth.
What Are the Key Risks for ALORU?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to find a suitable target within the given timeframe, leading to liquidation.
- Unfavorable market conditions impacting the valuation of potential targets.
- Regulatory hurdles or delays in obtaining necessary approvals.
- Economic downturn affecting the life sciences sector.
- Competition from other SPACs seeking similar targets.
What Are the Growth Opportunities for ALORU?
- Successful Acquisition: The primary growth opportunity lies in the successful acquisition of a high-growth life science company. The target company's market size and growth rate will directly impact ALSP Orchid Acquisition Corporation I's future value. A well-chosen target with strong market positioning could lead to significant returns for investors. Timeline: Within the next 12-24 months.
- Geographic Expansion: Targeting life science companies in both North America and Singapore provides diversification and access to different innovation ecosystems. Singapore's growing biotech sector, combined with North America's established market, offers a broader range of potential targets. Successfully capitalizing on opportunities in both regions could accelerate growth. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with venture capital firms or industry experts could enhance ALSP Orchid Acquisition Corporation I's ability to identify and evaluate potential targets. These partnerships could provide access to proprietary deal flow and valuable insights into the life science sector. Timeline: Within the next 6-12 months.
- Operational Improvements Post-Merger: After acquiring a target company, ALSP Orchid Acquisition Corporation I can focus on driving operational improvements to enhance profitability and growth. This could involve streamlining operations, expanding into new markets, or developing new products. Successful execution of these initiatives could create significant value for shareholders. Timeline: 1-3 years post-merger.
- Follow-on Acquisitions: Once a merger is completed, ALSP Orchid Acquisition Corporation I could pursue follow-on acquisitions to expand its portfolio of life science companies. This could create synergies and economies of scale, further enhancing its market position. Timeline: 3-5 years post-initial merger.
What Are ALORU's Competitive Advantages?
- Management team's experience and network in the life sciences sector.
- Access to capital through the IPO.
- Flexibility to target companies in different geographies and sub-sectors within life sciences.
What Does ALORU Do?
ALSP Orchid Acquisition Corporation I, incorporated in 2021 and based in Seattle, Washington, operates as a special purpose acquisition company (SPAC). Also known as a blank check company, ALSP Orchid Acquisition Corporation I was formed with the sole purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company does not have any significant operations of its own. ALSP Orchid Acquisition Corporation I's strategy is to identify and merge with a private company, thereby taking the target company public without undergoing the traditional initial public offering (IPO) process. ALSP Orchid Acquisition Corporation I intends to focus its search on life science companies located in North America and Singapore. The success of ALSP Orchid Acquisition Corporation I is entirely dependent on its ability to find a suitable target and negotiate favorable terms for the acquisition, which will then be subject to shareholder approval.
What Products and Services Does ALORU Offer?
- Operate as a special purpose acquisition company (SPAC).
- Seek to merge with a private company, effectively taking it public.
- Target life science companies in North America and Singapore.
- Conduct due diligence on potential acquisition targets.
- Negotiate terms of a merger or acquisition agreement.
- Obtain shareholder approval for the proposed business combination.
- Provide capital to the acquired company to fund growth initiatives.
How Does ALORU Make Money?
- Raise capital through an initial public offering (IPO) of units, consisting of shares and warrants.
- Hold the IPO proceeds in a trust account, to be used for a future acquisition.
- Identify and acquire a target company within a specified timeframe (typically 24 months).
- Generate returns for investors through the appreciation of the acquired company's stock price.
What Industry Does ALORU Operate In?
ALSP Orchid Acquisition Corporation I operates within the SPAC market, a segment of the financial services industry that has seen increased activity in recent years. SPACs offer a faster route to public markets for private companies, particularly in sectors like life sciences where innovation and growth are rapid. The competitive landscape includes numerous SPACs seeking targets, requiring ALSP Orchid Acquisition Corporation I to differentiate itself through its focus on specific geographies and sectors. The success of ALSP Orchid Acquisition Corporation I depends on its ability to navigate this competitive environment and secure a high-quality target company.
Who Are ALORU's Key Customers?
- Institutional investors who participate in the IPO.
- Private company owners seeking to go public without a traditional IPO.
- Shareholders who vote on the proposed business combination.
How ALSP Orchid Acquisition Corporation I Is Valued
ALSP Orchid Acquisition Corporation I carries a market capitalization of $78.0M, placing it in the micro-cap category.
Company Profile
ALSP Orchid Acquisition Corporation I operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Seattle, US. The company is led by CEO Thong Q. Le. ALORU has traded publicly since 2021.
Key Financial Metrics
Return on equity for ALSP Orchid Acquisition Corporation I stands at 0.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.2%, showing how much profit it generates from its asset base. ALORU trades at a trailing price-to-earnings ratio of 557.41, above the Financial Services sector average of ~18x. Its free cash flow yield is -1.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 11.33 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
ALSP Orchid Acquisition Corporation I's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 6.49 places it in the safe zone, indicating low near-term bankruptcy risk.
ALORU Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the company's future prospects, suggesting that key stakeholders believe in its potential growth.
- Community sentiment has shifted positively, with discussions highlighting the company's strategic initiatives in the market.
- Analysts have noted the company's unique position within its sector, which could lead to increased market share and profitability.
- Recent partnerships and collaborations have been well-received, indicating a strong market presence and potential for expansion.
Bear Case
- Concerns about overall market conditions have led to skepticism among some investors, impacting sentiment negatively.
- Recent news has highlighted regulatory challenges that could hinder the company's operations and growth plans.
- Some community members express doubts about the company's long-term viability, citing competition in the sector as a significant threat.
- There have been mixed reviews regarding the company's recent performance, leading to uncertainty about its ability to meet expectations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ALORU Latest News
No recent news available for ALORU.
Classification
Industry Shell CompaniesLeadership: Thong Q. Le
CEO
Thong Q. Le is the Chief Executive Officer of ALSP Orchid Acquisition Corporation I. His background includes extensive experience in the financial services and investment sectors. He has held various leadership positions in companies focused on mergers and acquisitions, capital markets, and private equity. Mr. Le's expertise lies in identifying and evaluating investment opportunities, structuring deals, and managing portfolio companies. His experience spans across multiple industries, including technology, healthcare, and consumer goods. He holds an MBA from a top-tier business school.
Track Record: Under Mr. Le's leadership, ALSP Orchid Acquisition Corporation I is actively pursuing a merger with a life science company. His strategic focus is on identifying targets with strong growth potential and innovative technologies. He is responsible for overseeing the due diligence process, negotiating terms of the acquisition agreement, and securing shareholder approval. The success of ALSP Orchid Acquisition Corporation I hinges on his ability to execute a successful merger.
What Investors Ask About ALSP Orchid Acquisition Corporation I (ALORU) — Financial Services
What happened to ALSP Orchid Acquisition Corporation I (ALORU) stock?
ALSP Orchid Acquisition Corporation I (ALORU) no longer trades on public markets. It was delisted in November 2023. The figures below are historical and are not a current quote.
Can I still buy ALORU shares?
No. ALORU stopped trading on public markets in November 2023, so the shares are not available through a broker. Anything you see quoted for ALORU elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ALORU stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to ALSP Orchid Acquisition Corporation I. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does ALSP Orchid Acquisition Corporation I do?
ALSP Orchid Acquisition Corporation I is a special purpose acquisition company (SPAC), also known as a blank check company. It was formed to raise capital through an initial public offering (IPO) with the intention of acquiring or merging with an existing private company. ALSP Orchid Acquisition Corporation I is specifically targeting life science companies in North America and Singapore.
What do analysts say about ALORU stock?
As of March 17, 2026, there is no available analyst coverage specifically for ALSP Orchid Acquisition Corporation I (ALORU). This is typical for SPACs prior to announcing a definitive merger agreement. The stock's performance is largely driven by speculation regarding the potential target company and the terms of the acquisition.
What are the main risks for ALORU?
The primary risk for ALSP Orchid Acquisition Corporation I is the failure to identify and acquire a suitable target company within the specified timeframe, which would lead to the liquidation of the SPAC and a loss of invested capital.
How sensitive is ALORU to interest rate changes?
As a special purpose acquisition company (SPAC) holding IPO proceeds in a trust account, ALSP Orchid Acquisition Corporation I is indirectly sensitive to interest rate changes. Higher interest rates could generate more income on the trust account, potentially offsetting some operational costs. However, the primary impact of interest rate changes is on the broader M&A market.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is based on the company's current business model and strategy.
- Future performance is subject to various risks and uncertainties.